Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/16671
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hersey, P. | - |
dc.contributor.author | Menzies, S. | - |
dc.contributor.author | Coventry, B. | - |
dc.contributor.author | Nguyen, T. | - |
dc.contributor.author | Farrelly, M. | - |
dc.contributor.author | Collins, S. | - |
dc.contributor.author | Hirst, D. | - |
dc.contributor.author | Johnson, H. | - |
dc.date.issued | 2005 | - |
dc.identifier.citation | Cancer Immunology Immunotherapy, 2005; 54(3):208-218 | - |
dc.identifier.issn | 0340-7004 | - |
dc.identifier.issn | 1432-0851 | - |
dc.identifier.uri | http://hdl.handle.net/2440/16671 | - |
dc.description | © Springer-Verlag 2004 | - |
dc.description.abstract | Previous studies in small groups of patients suggested that immunization of melanoma patients with peptide epitopes recognized by T cells could induce regression of melanoma. This approach was tested in 36 patients with stage IV melanoma. The (MHC class I– restricted) peptides were from gp100, MART-1, tyrosinase, and MAGE-3. The gp100 and MART-1 peptides had been modified to increase their immunogenicity. In half the patients (groups 3 and 4) the peptides were given in the adjuvant Montanide-ISA-720, and half the patients in both groups were given GM-CSF s.c. for 4 days following each injection. Treatment was well tolerated except for two severe erythematous responses to Montanide- ISA-720 and marked inflammatory responses at sites of GM-CSF administration in three patients. There were no objective clinical responses but stabilization of disease for periods from 3 to 12 months were seen in seven patients. Five of these were patients given the peptides in Montanide-ISA-720. Delayed-type hypersensitivity (DTH) skin test responses were also seen mainly in the patients given the peptides in Montanide- ISA-720. GM-CSF did not increase DTH responses in patients in the latter group but may have increased DTH responses in those not given peptides in Montanide-ISA- 720. Inflammatory responses around s.c. metastases or regional lymph nodes were observed in two patients. These results suggest that the peptides are more effective when given in the adjuvant Montanide-ISA-720. Nevertheless, results from this study, together with those from a number of comparable studies, indicate that peptide vaccines are currently of minimal benefit to patients and support the need for ongoing development of new strategies in treatment of this disease. | - |
dc.description.statementofresponsibility | Peter Hersey, Scott W. Menzies, Brendon Coventry, Tam Nguyen, Margaret Farrelly, Susan Collins, Debbie Hirst and Heather Johnson | - |
dc.language.iso | en | - |
dc.publisher | Springer-Verlag | - |
dc.source.uri | http://dx.doi.org/10.1007/s00262-004-0587-8 | - |
dc.subject | Adjuvants | - |
dc.subject | Clinical responses | - |
dc.subject | Melanoma | - |
dc.subject | Peptide vaccines | - |
dc.subject | T-cell responses | - |
dc.title | Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1007/s00262-004-0587-8 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Coventry, B. [0000-0002-3596-7735] | - |
Appears in Collections: | Aurora harvest 2 Surgery publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.